Gastrocrom Disease Interactions
There is 1 disease interaction with Gastrocrom (cromolyn).
Cromolyn (applies to Gastrocrom) renal/liver disease
Minor Potential Hazard, Low plausibility. Applicable conditions: Renal Dysfunction
Systemically absorbed cromolyn is eliminated almost equally by renal and biliary routes. Although less than 1% of an orally ingested dose and approximately 8% of an orally inhaled dose is systemically available, the manufacturers recommend that a dosage reduction be considered in patients with impaired renal or hepatic function.
References (7)
- Richards R, Dickson CR, Renwick AG, Lewis RA, Holgate ST (1987) "Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique." J Pharmacol Exp Ther, 241, p. 1028-32
- Rosenberg JL, Edlow D, Sneider R (1978) "Liver disease and vasculitis in a patient taking cromolyn." Arch Intern Med, 138, p. 989-91
- Neale MG, Brown K, Hodder RW, Auty RM (1986) "The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration." Br J Clin Pharmacol, 22, p. 373-82
- Fuller RW, Collier JG (1983) "The pharmacokinetic assessment of sodium cromoglycate." J Pharm Pharmacol, 35, p. 289-92
- Walker SR, Evans ME, Richards AJ, Paterson JW (1972) "The fate of [14C]disodium cromoglycate in man." J Pharm Pharmacol, 24, p. 525-31
- (2001) "Product Information. Intal (cromolyn)." Rhone Poulenc Rorer
- (2001) "Product Information. Gastrocrom (cromolyn)." Rhone Poulenc Rorer
Switch to consumer interaction data
Gastrocrom drug interactions
There is 1 drug interaction with Gastrocrom (cromolyn).
Report options
More about Gastrocrom (cromolyn)
- Gastrocrom consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- Drug class: mast cell stabilizers
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Prilosec
Prilosec (omeprazole) is used to treat symptoms of GERD and other conditions caused by excess ...
Prevacid
Prevacid is used to treat and prevent stomach and intestinal ulcers. Learn about side effects ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Midostaurin
Midostaurin is used for acute myeloid leukemia, systemic mastocytosis
Avapritinib
Avapritinib is used for gastrointestinal stromal tumor, systemic mastocytosis
Imatinib
Imatinib is used to treat certain types of leukemia, bone marrow disorders, and skin cancer ...
Lansoprazole
Lansoprazole is used to treat stomach and intestinal ulcers, erosive esophagitis and ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.